PMC:7605337 / 7896-8090 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T32","span":{"begin":12,"end":17},"obj":"Body_part"},{"id":"T33","span":{"begin":119,"end":131},"obj":"Body_part"}],"attributes":[{"id":"A32","pred":"fma_id","subj":"T32","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A33","pred":"fma_id","subj":"T33","obj":"http://purl.org/sig/ont/fma/fma62925"}],"text":"4) on human cells.14 Multiple monoclonal antibodies have been developed for SARS since 2002 that neutralized the spike glycoprotein on the SARS-COV surface.18−22 However, multiple escape mutatio"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T58","span":{"begin":76,"end":80},"obj":"Disease"},{"id":"T59","span":{"begin":139,"end":143},"obj":"Disease"}],"attributes":[{"id":"A58","pred":"mondo_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A59","pred":"mondo_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"4) on human cells.14 Multiple monoclonal antibodies have been developed for SARS since 2002 that neutralized the spike glycoprotein on the SARS-COV surface.18−22 However, multiple escape mutatio"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T69","span":{"begin":6,"end":17},"obj":"http://purl.obolibrary.org/obo/CLO_0053065"},{"id":"T70","span":{"begin":156,"end":158},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T71","span":{"begin":159,"end":161},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"}],"text":"4) on human cells.14 Multiple monoclonal antibodies have been developed for SARS since 2002 that neutralized the spike glycoprotein on the SARS-COV surface.18−22 However, multiple escape mutatio"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T31","span":{"begin":119,"end":131},"obj":"Chemical"}],"attributes":[{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"}],"text":"4) on human cells.14 Multiple monoclonal antibodies have been developed for SARS since 2002 that neutralized the spike glycoprotein on the SARS-COV surface.18−22 However, multiple escape mutatio"}

{"project":"LitCovid-PubTator","denotations":[{"id":"234","span":{"begin":6,"end":11},"obj":"Species"},{"id":"235","span":{"begin":139,"end":147},"obj":"Species"}],"attributes":[{"id":"A234","pred":"tao:has_database_id","subj":"234","obj":"Tax:9606"},{"id":"A235","pred":"tao:has_database_id","subj":"235","obj":"Tax:694009"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"4) on human cells.14 Multiple monoclonal antibodies have been developed for SARS since 2002 that neutralized the spike glycoprotein on the SARS-COV surface.18−22 However, multiple escape mutatio"}